secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001193125-23-211456
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha raises $150M PIPE; first Rett patient data shows clinical improvement
----------------------------------------------------------------------------

- Gross proceeds of $150M from PIPE: 122.4M shares at $0.90/share and 44.3M pre-funded warrants.
- Q2 2023 net loss $24.6M ($0.38/sh); cash $45.1M at June 30; PIPE extends runway into Q3 2025.
- First adult Rett patient dosed in REVEAL trial: TSHA-102 well-tolerated, no SAEs at 6 weeks.
- At 4 weeks, CGI-I score of 2 (much improved), RSBQ improved 23 points, patient gained ability to sit unassisted and hold objects.
- FDA cleared IND for TSHA-102 in pediatric Rett; CTA submitted to UK MHRA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/0001193125-23-211456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/d497848d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-211456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer